Stocknear Logo Stocknear
/
Popular
Login

United Therapeutics Corpo...

307.86
-0.41 (-0.13%)
At close: Apr 01, 2025, 3:03 PM

United Therapeutics Corporation Revenue Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015Dec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013Jun 30, 2013Mar 31, 2013Dec 31, 2012Sep 30, 2012Jun 30, 2012Mar 31, 2012Dec 31, 2011Jun 30, 2011
Adcirca Revenue 7M 5.7M 6.4M 6.8M 7.3M 7.5M 7.3M 10.4M 10.7M 10.4M 9.8M 8.1M 14.6M 23.6M 9.6M 21.6M 13.8M 19.4M 12.5M 27.8M 30.3M 29.1M 58.4M 41.7M 74.6M 109.8M 97.6M 93.1M 99.8M 120.6M 80M 112.7M 96M 90.9M 72.6M 91.58M 73.8M 68.08M 45.37M 73.55M 51.25M 55.32M 41.36M 52.05M 47.38M 43.73M 33.82M 38.18M 31.8M 30.22M 22.33M 22.65M 16.84M
Adcirca Revenue Growth +22.81% -10.94% -5.88% -6.85% -2.67% +2.74% -29.81% -2.80% +2.88% +6.12% +20.99% -44.52% -38.14% +145.83% -55.56% +56.52% -28.87% +55.20% -55.04% -8.25% +4.12% -50.17% +40.05% -44.10% -32.06% +12.50% +4.83% -6.71% -17.25% +50.75% -29.02% +17.40% +5.61% +25.21% -20.73% +24.10% +8.40% +50.06% -38.31% +43.51% -7.36% +33.74% -20.53% +9.86% +8.35% +29.29% -11.42% +20.05% +5.23% +35.35% -1.40% +34.46% n/a
Orenitram Revenue 113.2M 107.1M 106.2M 84.1M 92M 95.1M 88.2M 75.8M 87.5M 79M 82.8M 72.3M 85.2M 76.2M 72.4M 74M 74.7M 75.4M 69M 50.9M 62M 54M 24.9M 49.6M 53.8M 49.5M 52.2M 48M 52.5M 46M 39.3M 38.3M 40.7M 38M 40.2M 37.29M 34.39M 25.87M 20.89M 20.18M 14.46M 6.63M 136.11M 119.86M 132.32M 124.31M 114.68M 116.21M 120.81M 110.4M 110.55M 107.12M 104.89M
Orenitram Revenue Growth +5.70% +0.85% +26.28% -8.59% -3.26% +7.82% +16.36% -13.37% +10.76% -4.59% +14.52% -15.14% +11.81% +5.25% -2.16% -0.94% -0.93% +9.28% +35.56% -17.90% +14.81% +116.87% -49.80% -7.81% +8.69% -5.17% +8.75% -8.57% +14.13% +17.05% +2.61% -5.90% +7.11% -5.47% +7.81% +8.43% +32.93% +23.86% +3.52% +39.52% +118.03% -95.13% +13.55% -9.41% +6.44% +8.40% -1.32% -3.81% +9.43% -0.13% +3.20% +2.12% n/a
Product and Service, Other Revenue 5.5M 4.9M 6.2M 3.9M 1.9M 3.5M 2.5M 3.8M 114M 132M 131.7M 118.3M 125.4M 139.8M 130.2M 127.9M 124.5M 119M 145.3M 107.4M 168.3M 155.8M 155.5M 159.1M 153.6M 159.5M 126.8M 180.1M 187.3M 157.7M 145.8M 151.2M 152.4M 158.9M 139.8M 140.48M 150.07M 135.96M 146.28M 136.59M 142.88M 138.15M 107.09M 114.38M 120.31M 109.46M 94.64M 86.04M 88.3M 81.21M 70.07M 64.55M 61.81M
Product and Service, Other Revenue Growth +12.24% -20.97% +58.97% +105.26% -45.71% +40.00% -34.21% -96.67% -13.64% +0.23% +11.33% -5.66% -10.30% +7.37% +1.80% +2.73% +4.62% -18.10% +35.29% -36.19% +8.02% +0.19% -2.26% +3.58% -3.70% +25.79% -29.59% -3.84% +18.77% +8.16% -3.57% -0.79% -4.09% +13.66% -0.49% -6.39% +10.38% -7.06% +7.09% -4.40% +3.42% +29.01% -6.38% -4.92% +9.91% +15.65% +10.01% -2.57% +8.73% +15.90% +8.55% +4.43% n/a
Remodulin Revenue 128.3M 147.3M 128M 115.1M 131.1M 127.2M 121.4M 122.5M 257.7M 201M 172M 166.5M 164.2M 153.8M 123M 29.7M 129.5M 119.2M 102.9M 33.6M 110.8M 109.6M 103.8M 24.1M 107.8M 105.9M 94.6M 24.9M 88.9M 104.2M 87.4M 93.6M 101.8M 107M 102.2M 119.13M 121.72M 115.84M 113.38M 115.07M 119.69M 121.23M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Remodulin Revenue Growth -12.90% +15.08% +11.21% -12.20% +3.07% +4.78% -0.90% -52.46% +28.21% +16.86% +3.30% +1.40% +6.76% +25.04% +314.14% -77.07% +8.64% +15.84% +206.25% -69.68% +1.09% +5.59% +330.71% -77.64% +1.79% +11.95% +279.92% -71.99% -14.68% +19.22% -6.62% -8.06% -4.86% +4.70% -14.21% -2.13% +5.07% +2.17% -1.47% -3.86% -1.27% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Tyvaso Revenue 433.8M 398.2M 372.5M 676.4M 51.3M 318.9M 238.4M 242.3M 46.1M 44.5M 55.6M 50M 55.3M 53.1M 43.9M n/a 37.6M 29M 26.6M n/a 30.1M 25.1M 20M n/a 22.9M 19.8M 18M n/a 17M 16.1M 18M 13.2M 17.3M 17.8M 14.2M 15.71M 4.73M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Tyvaso Revenue Growth +8.94% +6.90% -44.93% +1218.52% -83.91% +33.77% -1.61% +425.60% +3.60% -19.96% +11.20% -9.58% +4.14% +20.96% n/a n/a +29.66% +9.02% n/a n/a +19.92% +25.50% n/a n/a +15.66% +10.00% n/a n/a +5.59% -10.56% +36.36% -23.70% -2.81% +25.35% -9.63% +232.29% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Unituxin Revenue 61.1M 51.7M 58.4M 54.2M n/a 44.3M 49.1M 36.7M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Unituxin Revenue Growth +18.18% -11.47% +7.75% n/a n/a -9.78% +33.79% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2013Dec 31, 2012Dec 31, 2011
Non-Us Revenue 125.3M 122.2M 121.3M 1.41B 1.03B 846.61M 676.97M
Non-Us Revenue Growth +2.54% +0.74% -91.41% +36.77% +21.95% +25.06% n/a
United States Revenue 2.2B 1.81B 1.56B n/a n/a n/a n/a
United States Revenue Growth +21.39% +15.98% n/a n/a n/a n/a n/a

Operating Expense Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 219.2M 177.6M 144.4M 132.2M 127.6M 130M 87.3M 166.1M 98.4M 141.5M 79M 127.9M 109.1M 112.8M 117.2M 158.7M 66.3M 105.9M 93M 105.2M 99.4M 39.6M 92M 79.2M 110.1M 83.1M -6.6M 159.1M 47.2M 67.4M 56.4M 139.5M 100.1M 72.2M 5M 148.56M -17.28M 109.99M 211.34M
Selling, General, and Administrative Revenue Growth +23.42% +22.99% +9.23% +3.61% -1.85% +48.91% -47.44% +68.80% -30.46% +79.11% -38.23% +17.23% -3.28% -3.75% -26.15% +139.37% -37.39% +13.87% -11.60% +5.84% +151.01% -56.96% +16.16% -28.07% +32.49% -1359.09% -104.15% +237.08% -29.97% +19.50% -59.57% +39.36% +38.64% +1344.00% -96.63% -959.93% -115.71% -47.96% n/a
Research and Development Revenue 103.5M 139.6M 104.1M 151.4M 84.7M 89M 82.9M 93.9M 66.1M 93.9M 69M 82.9M 79.2M 74.3M 303.7M 126.1M 68.7M 89.7M 73.2M 113.6M 85.7M 85.9M 897.4M 138.8M 101.1M 82.3M 35.7M 113.6M 55M 59.8M 36.2M 66.9M 45.9M 35.2M -400K 75.95M 9.53M 49.41M 110.21M
Research and Development Revenue Growth -25.86% +34.10% -31.24% +78.75% -4.83% +7.36% -11.71% +42.06% -29.61% +36.09% -16.77% +4.67% +6.59% -75.54% +140.84% +83.55% -23.41% +22.54% -35.56% +32.56% -0.23% -90.43% +546.54% +37.29% +22.84% +130.53% -68.57% +106.55% -8.03% +65.19% -45.89% +45.75% +30.40% -8900.00% -100.53% +697.19% -80.72% -55.17% n/a
Sales and Marketing Revenue 20.7M 25.4M 23.2M 24.1M 20.7M 20.1M 16.9M 23M 17.2M 16.1M 14.5M 16.4M 17.2M 17.1M 13.7M 16.8M 12.4M 12.7M 13M 18.6M 14.8M 13.7M 13.6M -28.9M n/a 15.6M 13.3M 17.6M 15.8M 15.5M 15.4M -67.1M 20.1M 24.7M 22.3M n/a n/a n/a n/a
Sales and Marketing Revenue Growth -18.50% +9.48% -3.73% +16.43% +2.99% +18.93% -26.52% +33.72% +6.83% +11.03% -11.59% -4.65% +0.58% +24.82% -18.45% +35.48% -2.36% -2.31% -30.11% +25.68% +8.03% +0.74% -147.06% n/a -100.00% +17.29% -24.43% +11.39% +1.94% +0.65% -122.95% -433.83% -18.62% +10.76% n/a n/a n/a n/a n/a

Create Price Alert on UTHR

Your price alert will notify you when the stock price is above 307.86.

Add to Watchlist